Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bristol Myers Squibb (NYSE: BMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings help investors understand how a global biopharmaceutical company in pharmaceutical preparation manufacturing manages its capital structure, reports financial results and communicates material events.
Recent Form 8-K filings from Bristol-Myers Squibb Company cover a range of topics. Some 8-Ks furnish quarterly earnings press releases and accompanying investor presentations, giving detail on financial performance and operating initiatives. Others describe the issuance of euro-denominated senior notes by a wholly owned Irish subsidiary, fully and unconditionally guaranteed by the company, including the terms of the notes, the governing indenture and the intended use of proceeds for tender offers and other corporate purposes. Additional 8-Ks outline cash tender offers for existing notes, early participation results, accepted amounts and pricing terms.
Filings also document corporate governance and executive matters, such as the departure of certain senior executives and related compensation arrangements, along with regular disclosures of dividend declarations. Regulation FD disclosures appear when the company posts investor presentations or updates on its website, and when it furnishes investor decks or webcasts tied to earnings calls and capital markets events.
On Stock Titan, these documents are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the significance of complex filings, from debt offerings and tender offers to earnings releases and Regulation FD presentations. Users can quickly see what each filing covers, identify items related to capital markets activity, dividends or governance, and then drill into the full text when deeper analysis is needed. This page is a practical starting point for reviewing Bristol Myers Squibb’s official disclosures that may affect BMY stock and related securities, including its listed notes and Celgene contingent value rights.
Bristol-Myers Squibb (BMY) furnished materials related to its third-quarter 2025 results. The company posted an earnings press release and an investor presentation on its website, and furnished them as Exhibits 99.1 and 99.2. The materials reference non-GAAP metrics, with reconciliations included in the press release.
The presentation supported the company’s Q3 2025 conference call and webcast at 8:00 a.m. Eastern time. Information furnished under Item 7.01, including Exhibits 99.1 and 99.2, is not deemed filed under the Exchange Act.
Cari Gallman, Executive Vice President and General Counsel at Bristol-Myers Squibb Company (BMY), reported a set of insider transactions on
The RSUs vest in three equal installments beginning on
Phyllis R. Yale, a director of Bristol-Myers Squibb Company (BMY), reported a transaction dated 09/30/2025 on a Form 4. The filing shows acquisition of 776.053 Deferred Share Units which will convert to shares of common stock upon settlement. After this transaction the reporting person beneficially owned 37,734.687 shares, a total that the filing says includes deferred compensation and dividends reinvested. The reported price for the deferred units is $0. The Form 4 is signed by an attorney-in-fact on behalf of Ms. Yale and dated 10/02/2025.
Michael R. McMullen, a director of Bristol-Myers Squibb Company (BMY), reported an acquisition on 09/30/2025 of 776.053 Deferred Share Units. Each Deferred Share Unit will convert into one share of common stock upon settlement, and the units become settleable when the reporting person ceases to be a director or at a previously specified future date. Following this transaction and prior deferred holdings, the filing shows the reporting person beneficially owns 10,076.278 shares (direct). The Form 4 was filed by an attorney-in-fact and signed on behalf of Mr. McMullen on 10/02/2025.
Peter J. Arduini, a director of Bristol-Myers Squibb Company (BMY), reported acquisition of 748.337 Deferred Share Units on 09/30/2025. Each Deferred Share Unit will convert into one share of common stock upon settlement; the units become settleable when the reporting person ceases to be a director or at a previously specified future date. After this transaction the filing shows the reporting person beneficially owns 64,620.164 shares (this total includes deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
David V. Elkins, Executive Vice President and Chief Financial Officer of Bristol-Myers Squibb Company (BMY), reported a sale of 56,000 shares of BMY common stock on 09/02/2025 at a weighted average price of $47.33 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2025, and the reported sale prices ranged from $47.075 to $47.820. After the transaction, Mr. Elkins beneficially owned 167,379 shares directly. In addition, the filing reports an indirect holding of 283.4 shares through the BMS Savings and Investment Program. The Form 4 was signed by an attorney-in-fact on 09/03/2025 and includes an undertaking to provide detailed per-price sale information upon request.
Wendy Short Bartie, EVP Corporate Affairs of Bristol-Myers Squibb Company (BMY), reported securities transactions on Form 4 showing restricted stock units vesting and shares withheld for taxes. On 09/01/2025, 1,235 restricted stock units converted into 1,235 shares of common stock (reported as acquisition at $0) under a vesting schedule that began 09/01/2023 and vests in four equal installments. Simultaneously, 632 shares were withheld to satisfy tax-withholding obligations at an indicated price of $47.18 per share. After these events, Ms. Bartie directly beneficially owned 5,669 shares.
Bristol-Myers Squibb Co. (BMY) filed a Form 144 notifying the proposed sale of 56,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $2,648,800.00. The filing reports total shares outstanding of 2,035,435,838 and an approximate sale date of 09/02/2025. The shares to be sold were acquired over 2021–2023 through stock option exercises and restricted stock vesting, with acquisition amounts listed by date (e.g., 2,976 on 08/12/2021; 19,326 on 09/13/2022). No securities were reported sold in the past three months.
Bristol-Myers Squibb (BMY) – Form 4 filing: EVP & Chief Medical Officer Cristian Massacesi reported the grant of 204,691 Restricted Stock Units (RSUs) on 08/01/2025. Each RSU converts into one share of BMY common stock upon vesting at no exercise cost.
Key terms:
- Vesting schedule: 25 % each year on the 1st–4th anniversaries of the grant date (first tranche 08/01/2026; final tranche 08/01/2029).
- Ownership after grant: Massacesi now holds 204,691 derivative securities directly.
- Transaction code: “A” (award) – no open-market purchase or sale occurred.
The award represents <0.01 % of BMY’s ~2.1 bn shares outstanding, so dilution is immaterial. The filing signals long-term incentive alignment but has no immediate earnings or cash-flow impact; therefore market effect should be minimal.